// App-Quantinova.ai

2270 : Identification of Optimal Subcutaneous Doses of Tocilizumab in Children with Polyarticular-Course Juvenile Idiopathic Arthritis

Researchers

Presenter

  • Hermine I. Brunner

Principal Investigators

  • Alberto Martini

  • Athimalaipet V. Ramanan

  • Rubn Cuttica

  • Jennifer E. Weiss

  • Michael Henrickson

  • Heinrike Schmeling

  • Jordi Anton

  • Kirsten Minden

  • Joy Hsu

  • Kamal Bharucha

  • Sunethra Wimalasundera

  • Alysha K. Kadva

  • Ruchi Upmanyu

  • Navita L. Mallalieu

  • Wendy Douglass

  • Daniel J Lovell

  • Fabrizio De Benedetti

Medical Centers

  • Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH

  • PRINTO Coordinating Ctr, Genoa, Italy

  • Bristol Royal Hospital for Children, Bristol, United Kingdom

  • Hospital de Ninos Pedro de Elizalde, Buenos Aires, Argentina

  • Hackensack University Medical Center, Oradell, NJ

  • Alberta Children's Hospital and University of Calgary, Calgary, Alberta, Canada

  • Hospital Sant Joan de Deu de Barcelona, Barcelona, Spain

  • Charite-University Medicine Berlin, Berlin, Germany

  • Roche Innovation Center, New York, NY

  • Roche/Genentech, South San Francisco, CA

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, GENOA, Italy

Locations

  • United States

  • Italy

  • United Kingdom

  • Argentina

  • Canada

  • Spain

  • Germany

Companies

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Methotrexate

  • Tocilizumab

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved